Treatment-free remission is now regarded as a primary aim of patients with long-term chronic myeloid leukemia (CML).
Starting with the approval of imatinib in 2001, the effectiveness of tyrosine kinase inhibitors (TKIs) has resulted in significant improvements in outcomes for CML patients, and with that success has come a focus on discontinuing treatment in patients when appropriate.
Results from trials such as the DADI (Dasatinib Discontinuation) and the STIM (Stop Imatinib) trials suggest this approach is feasible, and the National Comprehensive Cancer Network has modified its guidelines by incorporating TKI discontinuation in appropriately selected patients.
There are a number of factors that go into the decision to stop TKI treatments. They do come with side effects, as well as an accompanying impact on a patient s quality of life. These can include fatigue, nausea, sleep disturbance, and depression. Other issues include concerns about drug-drug interactions, financial toxicit
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
News provided by
Share this article
Share this article
NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for previously treated multiple myeloma. The XPOVIO regimens added to the NCCN guidelines, include: (i) selinexor / bortezomib / dexamethasone (once-weekly) (SVd); (ii) selinexor / daratumumab / dexamethasone (SDd); and (iii) selinexor / pomalidomide / dexamethasone (SPd), which is an all-oral treatment regimen. Importantly, the once weekly SVd regimen received a Category 1 recommendat
Share:
The investigational vaccine is the first-of-its-kind for type 1 diabetes to be tested in the United States and showed positive results in an early study in Europe
A City of Hope Phase 1 trial featuring an investigational vaccine that uses a person s own immune cells, a beta cell protein and vitamin D3 to potentially treat type 1 diabetes is now recruiting patients. The trial is part of The Wanek Family Project for Type 1 Diabetes at City of Hope, which seeks to find cures for the disease.
Bart O. Roep, Ph.D., City of Hope s Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes and director of The Wanek Family Project. (Photo: Business Wire)
What to Expect When Diagnosed with Head and Neck Cancer athensreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from athensreview.com Daily Mail and Mail on Sunday newspapers.
Experts Push for New Cancer Drug Dosing Recommendations medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.